deutetrabenazine
Selected indexed studies
- Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. (Lancet Psychiatry, 2017) [PMID:28668671]
- Deutetrabenazine Therapy and CYP2D6 Genotype. (, 2012) [PMID:31046213]
- Real-World Experience With Deutetrabenazine for Huntington Disease Chorea. (J Clin Pharmacol, 2024) [PMID:37565322]
_Worker-drafted node — pending editorial review._
Connections
deutetrabenazine is a side effect of
Sources
- Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. (2017) pubmed
- Deutetrabenazine Therapy and CYP2D6 Genotype. (2012) pubmed
- Real-World Experience With Deutetrabenazine for Huntington Disease Chorea. (2024) pubmed
- Deutetrabenazine in the treatment of Huntington's disease. (2019) pubmed
- Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review. (2024) pubmed
- Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease. (2017) pubmed
- Deutetrabenazine for the treatment of Huntington's chorea. (2018) pubmed
- Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data. (2019) pubmed
- Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease. (2024) pubmed
- Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia. (2020) pubmed